Navigation Links
FASgen Diagnostic Tests Identify Ovarian Cancer Progression and Apoptosis
Date:3/26/2008

BALTIMORE, March 26 /PRNewswire/ -- FASgen Diagnostics, LLC is pleased to report that results of studies using the Company's FAS-detect(TM) IHC and FAS- detect(TM) ELISA research tests were the subject of an address to Society of Gynecologic Oncologists annual meeting last week in Tampa, Florida. The report, "Over-expression of Fatty Acid Synthase (FAS) in Recurrent Ovarian Serous Carcinomas and its Potential Diagnostic and Therapeutic Role in Chemoresistant Disease," presented the data from studies conducted at the Johns Hopkins Oncology Center in cooperation with the Norwegian Radium Hospital.

The FAS-detect(TM) IHC test was used in evaluating 321 samples of serous ovarian cancer. FAS expression correlated with high grade disease and was an independent prognostic indicator. Patients with high levels of FAS expression survived for 36.9 months compared to 60.4 months for low expressors. Furthermore, FAS levels were highest in recurrent tumors. This is similar to prior findings in prostate and breast cancer. The FAS-detect(TM) ELISA was used to measure FAS levels in ovarian cancer ascites in 117 advanced stage serous carcinomas and 58 non-malignant controls, producing median results of 46.3 ng/ml of FAS in the ovarian cancer samples and 1.3 ng/ml in the controls.

The report further identifies the apoptotic effect of several FASi compounds from FASgen, Inc., an affiliated company of FASgen Diagnostics, LLC, which makes FASi compounds intended for therapeutic use in treating cancer. The results for FASgen's C-93 demonstrated significant apoptosis in SKOV3 and A2780 cell lines, i.e., > 70% within 48 hours. Similar findings were obtained with Taxol and Carboplatin resistant cell lines indicating that FAS inhibitors produce significant apoptosis to overcome hypoxia-induced chemoresistance. These in vitro data confirm the extensive xenograft results in ovarian, lung and colon cancers previously announced by FASgen. FAS is thus a promising target for ch
'/>"/>

SOURCE FASgen Diagnostics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FASgen Announces New Research Discoveries in Lung Cancer
2. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
3. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
4. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
5. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
6. Hypertension Diagnostics Announces Fiscal Year 2007 Results
7. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
8. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
9. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
10. Aloka to Unveil New ProSound Diagnostic Ultrasound System at the 17th World Congress on Ultrasound in Obstetrics and Gynecology, 7th to 11th of October 2007 in Florence, Italy
11. New peritoneal dialysis diagnostic discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Luciana Lagana and her husband Gregory ... feature film that received 9 awards at the 2014 Zed ... It is also an official selection of the 2014 PollyGrind ... cinematic career for James Noel, a young filmmaker who excels ... mystery, filmed in glorious black and white, watching Omadox will ...
(Date:11/27/2014)... November 27, 2014 An inventor from ... embarrassing fact of life, and she wants to lessen ... minutes later, I decided that there needed to be ... said. , Easy to use and producible in design ... a woman’s private areas throughout the day. It avoids ...
(Date:11/27/2014)... (HealthDay News) -- Most babies and young children don,t ... Food and Drug Administration says. Over-the-counter (OTC) cold ... younger than 2 because they could cause serious and ... adults average about three colds a year, but children ... parents might want to give them pain relievers, decongestants ...
(Date:11/27/2014)... 2014 The founders of VIM & VIGR, ... high functioning compression socks, are proud to announce the debut ... innovative Gradient Pressure (TM) knitting technology that is designed to ... VIGR’s commitment to adding flair and style to a product ... caught the eye of a writer at The New ...
(Date:11/27/2014)... OXNARD, CA (PRWEB) November 27, 2014 ... All-on-4™ dental implants procedure will help one person ... rehabilitation. , Dr. Saj Jivraj and Dr. Mamaly Reshad ... Woodland Hills, Calif., have launched a website devoted to ... A section of the website would be devoted to ...
Breaking Medicine News(10 mins):Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5
... nifedipine therapy and placebo, researchers say , , WEDNESDAY, Nov. ... used to prevent premature birth when women go into ... at maintaining pregnancy, after the initial spell of preterm ... who conducted the first ever placebo-controlled test of nifedipine ...
... Media coverage of clinical trials does not contain the ... of the coverage received by pharmaceutical and herbal remedy ... Medicine , has revealed that it is rarely possible ... the described research. , Tania Bubela from the University ...
... The American Veterinary Medical,Association (AVMA) Executive Board voted to ... dogs -- ear cropping and tail,docking. , ... AVMA opposes ear cropping and tail,docking of dogs when done ... ear cropping and tail docking from breed standards." , ...
... DRRX ) announced today that management is scheduled to present ... -- 20th Annual Piper Jaffray Health ... -- RBC Capital Markets 2008 ... A live audio webcast of ...
... ingredients can mean healthier eating without the guilt, experts ... A few healthy substitutions in your Thanksgiving recipes can ... sacrificing the taste, says the American Medical Association. ... swapping out a few ingredients with healthier alternatives, you ...
... (Nasdaq: HLTH ) announced today the preliminary results ... of its common stock at a price of $8.80 per ... on November 25, 2008. Based on the preliminary count ... the tender offer, 86,145,082 shares of common stock (including approximately ...
Cached Medicine News:Health News:Drug to Prevent Preterm Labor Shows Little Benefit 2Health News:Misleading media coverage of medicine 2Health News:AVMA Revises Policy on Ear Cropping and Tail Docking 2Health News:DURECT Corporation to Participate in Upcoming Healthcare Conferences 2Health News:Holiday Meals With a Calorie-Conscious Twist 2Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 2Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 3Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 4
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: ... (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... and Theravance Inc. (NASDAQ: THRX ). Free research ... . On Tuesday, November 25, 2014, the NASDAQ ... Average edged 0.02% lower, to finish the day at 17,814.94, ...
(Date:11/26/2014)... Nov. 26, 2014  CARsgen, a leader in the ... to treat a variety of cancers, today announced the ... a China -based healthcare private equity ... focused on the development of new therapeutics for liver, ... Cancer Institute and Shanghai Renji Hospital, the company plans ...
(Date:11/26/2014)... CHARLOTTE, N.C. , Nov. 25, 2014  At ... San Antonio this October, KaVo Kerr Group ... Institute Technology Expo, offering attendees the opportunity to see ... to well-respected key opinion leaders deliver lectures on the ... Kerr Group products include the new DEXIS CariVu Caries ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
Bravo Vacuum Pump Accessories Kit (One canister, one lid, one "O" ring tube, one tubing set)...
The pouch is designed to protect the Digitrapper. The pouch strap can be worn on a belt loop or carried in a shoulder strap or backpack configuration....
... designed using established technology providing a ... ,Working with pH catheters with ... multi-use catheter is used the Hellige ... the skin.,NOTE: ,Medtronic pH measurement systems ...
...
Medicine Products: